Evidence map›Paper›PMID 31034483›Full record

ArticlePloS one2019

Exploring the hereditary background of renal cancer in Denmark.

Maria Bejerholm Christensen, Karin Wadt, Uffe Birk Jensen, Charlotte Kvist Lautrup, Anders Bojesen, Lotte Nylandsted Krogh, Thomas van Overeem Hansen, Anne-Marie Gerdes

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Renal Cell Cancer and Obesity.International journal of molecular sciences · 2022
    Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Maria Bejerholm ChristensenDepartment of Clinical Genetics, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0001-5428-0739
Karin WadtDepartment of Clinical Genetics, Copenhagen University Hospital, Copenhagen, Denmark.
Uffe Birk JensenDepartment of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark.
Charlotte Kvist LautrupDepartment of Clinical Genetics, Aalborg University Hospital, Aalborg, Denmark.
Anders BojesenDepartment of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark.
Lotte Nylandsted KroghDepartment of Clinical Genetics, Odense University Hospital, Odense, Denmark.
Thomas van Overeem HansenDepartment of Clinical Genetics, Copenhagen University Hospital, Copenhagen, Denmark.
Anne-Marie GerdesDepartment of Clinical Genetics, Copenhagen University Hospital, Copenhagen, Denmark.
Copenhagen University Hospital · DKAarhus University Hospital · DKAalborg University Hospital · DKOdense University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEvery year more than 800 patients in Denmark are diagnosed with renal cell carcinoma (RCC) of which 3-5% are expected to be part of a hereditary renal cancer syndrome. We performed genetic screening of causative and putative RCC-genes (VHL, FH, FLCN, MET, SDHB, BAP1, MITF, CDKN2B) in RCC-patients suspected of a genetic predisposition.

methodsThe cohort consisted of forty-eight Danish families or individuals with early onset RCC, a family history of RCC, a family history of RCC and melanoma or both RCC- and melanoma diagnosis in the same individual. DNA was extracted from peripheral blood samples or cancer-free formalin-fixed paraffin-embedded tissue.

resultsOne start codon variant of unknown clinical significance (VUS) (c.3G>A, p.Met1Ile) and one missense VUS (c.631A>C, p.Met211Leu) was found in VHL in a patient with RCC-onset at twenty-eight years of age but without other manifestations or family history of von Hippel-Lindau (VHL). Furthermore, in three families we found three different variants in BAP1, one of which was a novel non-segregating missense variant (c.1502G>A, p.Ser501Asn) in a family with two brothers affected with RCC. Finally, we found the known E318K-substitution in MITF in a RCC-affected member of a family with multiple melanomas. No variants were detected in CDKN2B.

conclusionAlthough we did find three VUS's in BAP1 in three families and a pathogenic variant in MITF in one family, pathogenic germline variants in BAP1, MITF or CDKN2B are not frequent causes of hereditary renal cancer in Denmark. It is possible that the high prevalence of risk factors such as male gender, smoking and obesity has influenced the development of cancer in the patients of the current study. Further investigations into putative predisposing genes and risk factors of RCC are necessary to enable better prediction of renal cancer risk or presymptomatic testing of relatives in hereditary renal cancer families.

Indexed as

AdultAgedAged, 80 and overAge of OnsetCarcinoma, Renal CellCohort StudiesCyclin-Dependent Kinase Inhibitor p15DenmarkFemaleGenetic Predisposition to DiseaseGenetic TestingGenetic VariationHumansKidney NeoplasmsMaleMelanomaBAP1 protein, humanCDKN2B protein, humanCyclin-Dependent Kinase Inhibitor p15Microphthalmia-Associated Transcription FactorMITF protein, humanTumor Suppressor ProteinsUbiquitin ThiolesteraseVHL protein, humanVon Hippel-Lindau Tumor Suppressor Protein

Identifiers

PMID31034483
PMCPMC6488054
OpenAlexW2943033257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.